Central Nervous System Biomarkers Market Research Report Information by Type Procedure (Safety, Efficacy, Validation Biomarker), Application (Drug Discovery & Development, Personalized Medicine), End Use (Diagnostic Labs, Hospitals & Clinics, Research Centers), and Region (North America, Europe, Asia-Pacific, Rest of the World)—Forecast to 2032

TABLE OF CONTENTS

1. EXCECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Application

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Impact on Supply Chain

5.3.3. Regional Impact

5.3.4. Opportunity and Threat Analysis

6. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE

6.1. Overview

6.2. Safety Biomarker

6.3. Efficacy Biomarker

6.4. Validation Biomarker

6.5. Others

7. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION

7.1. Overview

7.2. Drug Discovery & Development

7.3. Personalized Medicine

7.4. Others

8. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USE

8.1. Overview

8.2. Diagnostic Labs

8.3. Clinics/Hospitals

8.4. Research Centers

9. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY REGION

9.1. Overview

9.1. North America

9.1.1. US

9.1.2. Canada

9.2. Europe

9.2.1. Germany

9.2.2. France

9.2.3. UK

9.2.4. Italy

9.2.5. Spain

9.2.6. Rest of Europe

9.3. Asia-Pacific

9.3.1. China

9.3.2. India

9.3.3. Japan

9.3.4. South Korea

9.3.5. Australia

9.3.6. Rest of Asia-Pacific

9.4. Rest of the World

9.4.1. Middle East

9.4.2. Africa

9.4.3. Latin America

10. COMPANY LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Central Nervous System Biomarkers Market

10.5. Competitive Benchmarking

10.6. Leading Players in terms of Number of Developments in the Global Central Nervous System Biomarkers Market

10.7. Key Developments and Growth Strategies

10.7.1. New ProductLaunch/Service Deployment

10.7.2. Merger &Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix

10.8.1. Sales & Operating Income, 2020

10.8.2. Major Players R&D Expenditure, 2020

11. COMPANY PROFILES

11.1. Thermo Fisher Scientific (US)

11.1.1. Company Overview

11.1.2. Financial Overview

11.1.3. Products Offered

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Merck & Co (US)

11.3. AbaStar MDx Inc (US)

11.4. Abiant, Inc (US)

11.5. Avacta Group Plc (UK)

11.6. Diagenic Asa (Norway)

11.7. Banyan Biomarkers (US)

11.8. Avid Radiopharmaceuticals Inc (US)

11.9. Acumen pharmaceuticals Inc (US)

11.10. Siemens AG (Germany)

11.11. Novartis (Switzerland)

11.12. Others

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SYNOPSIS, 2018–2027

TABLE 2 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET ESTIMATES & FORECAST, 2018–2027 (USD MILLION)

TABLE 3 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 4 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 5 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 6 NORTH AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 7 NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 8 NORTH AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 9 US: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 10 US CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 11 US: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 12 CANADA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 13 CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 14 CANADA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 15 EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 16 EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 17 EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 18 GERMANY: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 19 GERMANY: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 20 GERMANY: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 21 FRANCE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 22 FRANCE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 23 FRANCE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 24 ITALY: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 25 ITALY: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 26 ITALY: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 27 SPAIN: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 28 SPAIN: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 29 SPAIN: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 30 UK: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 31 UK: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 32 UK: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 33 REST OF EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 34 REST OF EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 35 REST OF EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 36 ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 37 ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 38 ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 39 JAPAN: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 40 JAPAN: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 41 JAPAN: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 42 CHINA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 43 CHINA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 44 CHINA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 45 INDIA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 46 INDIA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 47 INDIA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 48 AUSTRALIA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 49 AUSTRALIA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, APPLICATION, 2018–2027 (USD MILLION)

TABLE 50 AUSTRALIA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, END USER, 2018–2027 (USD MILLION)

TABLE 51 SOUTH KOREA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 52 SOUTH KOREA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, APPLICATION, 2018–2027 (USD MILLION)

TABLE 53 SOUTH KOREA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, END USER, 2018–2027 (USD MILLION)

TABLE 54 REST OF ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 55 REST OF ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 56 REST OF ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 57 REST OF THE WORLD: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 58 REST OF THE WORLD: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, APPLICATION 2018–2027 (USD MILLION)

TABLE 59 REST OF THE WORLD: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, END USER, 2018–2027 (USD MILLION)

TABLE 60 MIDDLE EAST: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 61 MIDDLE EAST: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, APPLICATION 2018–2027 (USD MILLION)

TABLE 62 MIDDLE EAST: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, END USER, 2018–2027 (USD MILLION)

TABLE 63 AFRICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 64 AFRICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, APPLICATION 2018–2027 (USD MILLION)

TABLE 65 AFRICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, END USER, 2018–2027 (USD MILLION)

TABLE 66 LATIN AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 67 LATIN AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, APPLICATION 2018–2027 (USD MILLION)

TABLE 68 LATIN AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, END USER, 2018–2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET

FIGURE 4 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY TYPE, 2020 (%)

FIGURE 5 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY APPLICATION, 2020 (%)

FIGURE 6 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY END USER, 2020 (%)

FIGURE 7 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 8 NORTH AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 11 REST OF THE WORLD: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 12 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 13 THERMO FISHER SCIENTIFIC: KEY FINANCIALS

FIGURE 14 THERMO FISHER SCIENTIFIC: SEGMENTAL REVENUE

FIGURE 15 THERMO FISHER SCIENTIFIC: REGIONAL REVENUE

FIGURE 16 MERCK & CO.: KEY FINANCIALS

FIGURE 17 MERCK & CO.: SEGMENTAL REVENUE

FIGURE 18 MERCK & CO.: REGIONAL REVENUE

FIGURE 19 ABASTAR MDX INC.: KEY FINANCIALS

FIGURE 20 ABASTAR MDX INC..: SEGMENTAL REVENUE

FIGURE 21 ABASTAR MDX INC.: REGIONAL REVENUE

FIGURE 22 ABIANT, INC.: KEY FINANCIALS

FIGURE 23 ABIANT, INC.: SEGMENTAL REVENUE

FIGURE 24 ABIANT, INC.: REGIONAL REVENUE

FIGURE 25 AVACTA GROUP PLC: KEY FINANCIALS

FIGURE 26 AVACTA GROUP PLC: SEGMENTAL REVENUE

FIGURE 27 AVACTA GROUP PLC: REGIONAL REVENUE

FIGURE 28 DIAGENIC ASA: KEY FINANCIALS

FIGURE 29 DIAGENIC ASA: SEGMENTAL REVENUE

FIGURE 30 DIAGENIC ASA: REGIONAL REVENUE

FIGURE 31 BANYAN BIOMARKERS: KEY FINANCIALS

FIGURE 32 BANYAN BIOMARKERS: SEGMENTAL REVENUE

FIGURE 33 BANYAN BIOMARKERS: REGIONAL REVENUE

FIGURE 34 AVID RADIOPHARMACEUTICALS INC.: KEY FINANCIALS

FIGURE 35 AVID RADIOPHARMACEUTICALS INC.: SEGMENTAL REVENUE

FIGURE 36 AVID RADIOPHARMACEUTICALS INC.: REGIONAL REVENUE

FIGURE 37 ACUMEN PHARMACEUTICALS INC.: KEY FINANCIALS

FIGURE 38 ACUMEN PHARMACEUTICALS INC.: SEGMENTAL REVENUE

FIGURE 39 ACUMEN PHARMACEUTICALS INC.: REGIONAL REVENUE

FIGURE 40 SIEMENS AG: KEY FINANCIALS

FIGURE 41 SIEMENS AG: SEGMENTAL REVENUE

FIGURE 42 SIEMENS AG: REGIONAL REVENUE

FIGURE 43 NOVARTIS AG: KEY FINANCIALS

FIGURE 44 NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 45 NOVARTIS AG: REGIONAL REVENUE